Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
104.32
-1.01 (-0.96%)
Real-time:   10:32AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 103.76 - 106.89
52 week 74.83 - 141.58
Open 105.11
Vol / Avg. 118,633.00/1.32M
Mkt cap 8.21B
P/E 30.37
Div/yield     -
EPS 3.44
Shares 78.69M
Beta 0.99
Inst. own 97%
Aug 6, 2015
Q2 2015 Medivation Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 Medivation Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 16, 2015
Medivation Inc Annual Shareholders Meeting
May 18, 2015
Medivation Inc at UBS Global Healthcare Conference
May 7, 2015
Q1 2015 Medivation Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Medivation Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2.41% 38.91%
Operating margin 0.44% 39.67%
EBITD margin - 40.41%
Return on average assets -1.36% 42.39%
Return on average equity -2.72% 105.07%
Employees 485 -
CDP Score - -

Address

525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Richard A. Bierly Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Andrew Kenneth William Powell Senior Vice President, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Joseph M. Lobacki Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Lynn Seely M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 51
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 54
Bio & Compensation  - Reuters
Dawn Svoronos Independent Director
Age: 61
Bio & Compensation  - Reuters
W. Anthony Vernon Independent Director
Age: 59
Bio & Compensation  - Reuters